Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/11/2017
SIETES contiene 92130 citas

 
 
 1 a 20 de 1139 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Lee-HY, Ban G-Y, Jeong C-G, Lee JH, Park SH, Kim SH, Lee Y-H, Ye Y-M. Propacetamol poses a potential harm of adverse hypotension in male and older patients. Pharmacoepidemiol Drug Saf 2017;26:256-64. [Ref.ID 102062]
2.Tiene citas relacionadas Cita con resumen
Eunjung Cha A. Monthly shot could be the ‘next revolution’ in HIV therapy, replacing daily pills. The Washington Post 2017:1. [Ref.ID 101921]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Feuerstein A. STAT Plus: Strong results for a new HIV drug will be a big boost to Gilead Sciences. STAT 2017:24 de julio. [Ref.ID 101919]
4. Cita con resumen
Becker WC, Fiellin DA. Abuse-deterrent opioid formulations - Putting the potential benefits into perspective. N Engl J Med 2017;376:2103-5. [Ref.ID 101625]
5. Cita con resumen
Anónimo. Drugs for menopausal symptoms. Med Lett Drugs Ther 2016;58:142-5. [Ref.ID 100946]
6. Cita con resumen
Anónimo. Genmab, J&J post data allowing for faster dosing of daratumumab. DIA Daily 2016:5. [Ref.ID 100880]
7. Cita con resumen
Anónimo. NICE reverses decision, recommends apremilast. DIA Daily 2016:2. [Ref.ID 100805]
8.Tiene citas relacionadas Cita con resumen
Dunlap B, Cifu AS. Clinical management of opioid use disorder. JAMA 2016;316:338-9. [Ref.ID 100637]
9.Tiene citas relacionadas Cita con resumen
Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ, for the PRO-814 Study Group. Effect of buprenorphine implant on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial. JAMA 2016;316:282-90. [Ref.ID 100636]
10. Cita con resumen
Anónimo. Cannabis and cannabinoids. Med Lett Drugs Ther 2016;58:97-8. [Ref.ID 100510]
13.Tiene citas relacionadas
Wang C, Wong S, Graham DJ. Risk of anaphylaxis with intravenous iron products. JAMA 2016;315:2232-3. [Ref.ID 100367]
14.Tiene citas relacionadas
DeLoughery TG. Risk of anaphylaxis with intravenous iron products. JAMA 2016;315:2232. [Ref.ID 100366]
15. Cita con resumen
Anónimo. FDA approves first buprenorphine implant for treatment of opioid dependence. FDA U.S. Food and Drug Administration 2016:26 de mayo. [Ref.ID 100323]
16. Cita con resumen
Jian Z, Li H, Race NS, Ma T, Jin H, Yin Z. Is the Era of intravenous proton pump inhibitors coming to an end in patients with bleeding peptic ulcers? meta-analysis of the published literature.. Br J Clin Pharmacol 2015:18 de diciembre. [Ref.ID 99821]
17.Tiene citas relacionadas
Connors JM. Antidote for factor Xa anticoagulants. N Engl J Med 2015;373:2471-2. [Ref.ID 99801]
18. Cita con resumen
Baten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, MEASURE 1 Study Group, MEASURE 2 Study Group. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 2015;373:2534-48. [Ref.ID 99800]
19. Cita con resumen
Dyer O. Canada is to legalise recreational marijuana . BMJ 2015;351:h6758. [Ref.ID 99753]
20.Tiene citas relacionadas Cita con resumen
Wang C, Graham DJ, Kane RC, Xie D, Wemecke M, Levenson M, MaCurdy TE, Houstoun M, Ryan Q, Wong S, Mott K, Sheu T-C, Limb S, Worrall C, Kelman JA, Reichman ME. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 2015;314:2062-8. [Ref.ID 99687]
Seleccionar todas
 
 1 a 20 de 1139 siguiente >>